A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma.

MicroRNAs (miRNAs) play an important role in carcinogenesis through the regulation of their target genes. miRNA-related single nucleotide polymorphisms (miR-SNPs) can affect miRNA biogenesis and target sites and can alter microRNA expression and functions. We examined 11 miR-SNPs, including 5 in mic...

Full description

Bibliographic Details
Main Authors: Marc Campayo, Alfons Navarro, Nuria Viñolas, Rut Tejero, Carmen Muñoz, Tania Diaz, Ramon Marrades, Maria L Cabanas, Josep M Gimferrer, Pere Gascon, Jose Ramirez, Mariano Monzo
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3143163?pdf=render
id doaj-3077e8042fc744ea8e03494f6d8ae823
record_format Article
spelling doaj-3077e8042fc744ea8e03494f6d8ae8232020-11-25T02:03:31ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0167e2250910.1371/journal.pone.0022509A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma.Marc CampayoAlfons NavarroNuria ViñolasRut TejeroCarmen MuñozTania DiazRamon MarradesMaria L CabanasJosep M GimferrerPere GasconJose RamirezMariano MonzoMicroRNAs (miRNAs) play an important role in carcinogenesis through the regulation of their target genes. miRNA-related single nucleotide polymorphisms (miR-SNPs) can affect miRNA biogenesis and target sites and can alter microRNA expression and functions. We examined 11 miR-SNPs, including 5 in microRNA genes, 3 in microRNA binding sites and 3 in microRNA-processing machinery components, and evaluated time to recurrence (TTR) according to miR-SNP genotypes in 175 surgically resected non-small-cell lung cancer (NSCLC) patients. Significant differences in TTR were found according to KRT81 rs3660 (median TTR: 20.3 months for the CC genotype versus 86.8 months for the CG or GG genotype; P = 0.003) and XPO5 rs11077 (median TTR: 24.7 months for the AA genotype versus 73.1 months for the AC or CC genotypes; P = 0.029). Moreover, when patients were divided according to stage, these differences were maintained for stage I patients (P = 0.002 for KRT81 rs3660; P<0.001 for XPO5 rs11077). When patients were divided into sub-groups according to histology, the effect of the KRT81 rs3660 genotype on TTR was significant in patients with squamous cell carcinoma (P = 0.004) but not in those with adenocarcinoma. In the multivariate analyses, the KRT81 rs3660 CC genotype (OR = 1.8; P = 0.023) and the XPO5 rs11077 AA genotype (OR = 1.77; P = 0.026) emerged as independent variables influencing TTR. Immunohistochemical analyses in 80 lung specimens showed that 95% of squamous cell carcinomas were positive for KRT81, compared to only 19% of adenocarcinomas (P<0.0001). In conclusion, miR-SNPs are a novel class of SNPs that can add useful prognostic information on the clinical outcome of resected NSCLC patients and may be a potential key tool for selecting high-risk stage I patients. Moreover, KRT81 has emerged as a promising immunohistochemical marker for the identification of squamous cell lung carcinoma.http://europepmc.org/articles/PMC3143163?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Marc Campayo
Alfons Navarro
Nuria Viñolas
Rut Tejero
Carmen Muñoz
Tania Diaz
Ramon Marrades
Maria L Cabanas
Josep M Gimferrer
Pere Gascon
Jose Ramirez
Mariano Monzo
spellingShingle Marc Campayo
Alfons Navarro
Nuria Viñolas
Rut Tejero
Carmen Muñoz
Tania Diaz
Ramon Marrades
Maria L Cabanas
Josep M Gimferrer
Pere Gascon
Jose Ramirez
Mariano Monzo
A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma.
PLoS ONE
author_facet Marc Campayo
Alfons Navarro
Nuria Viñolas
Rut Tejero
Carmen Muñoz
Tania Diaz
Ramon Marrades
Maria L Cabanas
Josep M Gimferrer
Pere Gascon
Jose Ramirez
Mariano Monzo
author_sort Marc Campayo
title A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma.
title_short A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma.
title_full A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma.
title_fullStr A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma.
title_full_unstemmed A dual role for KRT81: a miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma.
title_sort dual role for krt81: a mir-snp associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2011-01-01
description MicroRNAs (miRNAs) play an important role in carcinogenesis through the regulation of their target genes. miRNA-related single nucleotide polymorphisms (miR-SNPs) can affect miRNA biogenesis and target sites and can alter microRNA expression and functions. We examined 11 miR-SNPs, including 5 in microRNA genes, 3 in microRNA binding sites and 3 in microRNA-processing machinery components, and evaluated time to recurrence (TTR) according to miR-SNP genotypes in 175 surgically resected non-small-cell lung cancer (NSCLC) patients. Significant differences in TTR were found according to KRT81 rs3660 (median TTR: 20.3 months for the CC genotype versus 86.8 months for the CG or GG genotype; P = 0.003) and XPO5 rs11077 (median TTR: 24.7 months for the AA genotype versus 73.1 months for the AC or CC genotypes; P = 0.029). Moreover, when patients were divided according to stage, these differences were maintained for stage I patients (P = 0.002 for KRT81 rs3660; P<0.001 for XPO5 rs11077). When patients were divided into sub-groups according to histology, the effect of the KRT81 rs3660 genotype on TTR was significant in patients with squamous cell carcinoma (P = 0.004) but not in those with adenocarcinoma. In the multivariate analyses, the KRT81 rs3660 CC genotype (OR = 1.8; P = 0.023) and the XPO5 rs11077 AA genotype (OR = 1.77; P = 0.026) emerged as independent variables influencing TTR. Immunohistochemical analyses in 80 lung specimens showed that 95% of squamous cell carcinomas were positive for KRT81, compared to only 19% of adenocarcinomas (P<0.0001). In conclusion, miR-SNPs are a novel class of SNPs that can add useful prognostic information on the clinical outcome of resected NSCLC patients and may be a potential key tool for selecting high-risk stage I patients. Moreover, KRT81 has emerged as a promising immunohistochemical marker for the identification of squamous cell lung carcinoma.
url http://europepmc.org/articles/PMC3143163?pdf=render
work_keys_str_mv AT marccampayo adualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT alfonsnavarro adualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT nuriavinolas adualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT ruttejero adualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT carmenmunoz adualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT taniadiaz adualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT ramonmarrades adualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT marialcabanas adualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT josepmgimferrer adualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT peregascon adualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT joseramirez adualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT marianomonzo adualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT marccampayo dualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT alfonsnavarro dualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT nuriavinolas dualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT ruttejero dualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT carmenmunoz dualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT taniadiaz dualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT ramonmarrades dualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT marialcabanas dualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT josepmgimferrer dualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT peregascon dualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT joseramirez dualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
AT marianomonzo dualroleforkrt81amirsnpassociatedwithrecurrenceinnonsmallcelllungcancerandanovelmarkerofsquamouscelllungcarcinoma
_version_ 1724947639196188672